medigraphic.com
ISSN 1560-4381 (Print)

2016, Number 2

<< Back Next >>

Correo Científico Médico 2016; 20 (2)

Role of metabolic reprogramming in carcinogenesis

Alonso RA, Pérez CM, Vidal PZ, Vidal PA

Language: Spanish
References: 37
Page: 292-304
PDF size: 406.50 Kb.


ABSTRACT

The role of the genes that suppress tumors and oncogenes in cellular cycle control is known but its effect in tumoral metabolism is a novel topic in the modern oncology. Nowadays the concept of metabolic reprograming in tumors has been reexamined as an important process related to carcinogenesis. A literature review was done in PubMed database by using descriptors such as genes, suppressor and metabolism; oncogenes and metabolism; neoplasms and metabolism. Oncogenes mutations of code for PI3K, AKT, mTORC and Myc induce an increase of the expression of isoenzimes of the glycolytic path, while they inhibit oxidative phosphorylation. This makes possible anabolic metabolism. They are also related to an increase in glucose consumption rates and the release of lactase to the tumoral microenvironment. The importance of anabolic metabolism in cancer progression has been proved in tumor cells, which is another option in the treatment of the disease.


REFERENCES

  1. Becker WM, Kleinsmiht LJ, Hardin J. El mundo de la célula. 6ta ed. Madrid: Addison Wesly; 2007

  2. Karp G. Biología celular y molecular.5ta ed .México: Mc Graw Hill; 2009

  3. Lu J, Tan M, Cai Q. The Warburg effect in tumor progression: Mitochondrial oxidative metabolism as an anti-metastasis mechanism. Cancer Lett. 2015[citado 1 feb 2016]; 356(2 Part A):156-164.Dipsonible en: http://www.sciencedirect.com/science/article/pii/S0304383514002079

  4. Jiménez BN, Vega RJ, Barguil Meza I. Acidosis láctica tipo b1 secundaria a linfoma de burkitt. Rev. Clín Esc Med UCR-HSJD. 2012[citado 1 feb 2016]; 2(5):1-4.Disponible en: http://www.revistas.ucr.ac.cr/index.php/clinica/article/view/6512/6210

  5. Santandreu Jaume FM. Cáncer de colon: nuevos hallazgos moleculares y posible importancia clínica. Medici Balear. 2013[citado 2 jun 2014]; 28 (1): 35-40 Disponible en: http://ibdigital.uib.es/greenstone/collect/medicinaBalear/archives/Medicina/_Balear_/2013v28n/1p035.dir/Medicina_Balear_2013v28n1p035.pdf

  6. Koppenol WH, Bounds PL, Dang CV. Otto Warburg's contributions to current concepts of cancer metalabolism. Nat Rev Cancer. 2011 [citado 2 jun 2014]; 11(5):325-337.Disponible en: http://www.nature.com/nrc/journal/v11/n5/full/nrc3038.html

  7. Ward PS, Thompson CB. Metabolic Reprograming: A cancer Hallmark even Waburg did not anticipate. Cancer Cell. 2012[citado 2 jun 2014]; 21(3):297-308.Disponible en: http://www.sciencedirect.com/science/article/pii/S1535610812000785

  8. Hanahan D, Weinberg RA. Hallmark of cacer: Net generations. Cell. 2011[citado 1 feb 2016]; 144(5):646-674.Disponible en: http://www.cell.com/cell/abstract/S0092-8674%2811%290

  9. Lurlaro R, León-Annicchiarico CL, Muñoz-Pinedo C. Regulation of cancer metabolism by oncogenes and tumor suppressors. Methods Enzymol. 2014[citado 2 jun 2014]; 542:59-80.Disponible en:http://www.sciencedirect.com/science/article/pii/B9780124166189000030

  10. 10.Álvarez Estrabao OA, Cruz Mariño T, Concepción Osorio M, Cardet Escalona M, Díaz Armas MT. Asesoramiento genético sobre el cáncer de mama. CCM.2012 [citado 1 ene 2016]; 16(2). Disponible en: www.revcocmed.sld.cu/index.php/cocmed/article/view/506/70

  11. Ortigoza Garcell RI. Miguel Soca PE, Machín Batista D. Variantes genéticas en el cáncer de mama. CCM. 2012[citado 1 feb 2016]; 16(4).Disponible en: http://revcocmed.sld.cu/index.php/cocmed/article/view/737/230

  12. 12.Ávila Mora MC, Sansarí Baro JT, Pavón Gómez V. Genes en el cáncer de cuello uterino. CCM.2012 [citado 1 feb 2016]; 17(1).Disponible en: http://revcocmed.sld.cu/index.php/cocmed/article/view/969/263

  13. Ledford H. Metabolic quirks yield tumour hope .Nature. 2014[citado 2 jun 2014]; 508(7495): 158–159.Disponible en: http://www.nature.com/news/metabolic-quirks-yield-tumour-hope-1.15005

  14. Liem Minh P, Sai-Ching Jim Y, and Mong-Hong L. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med. 2014 [2 citado jun 2014]; 11(1):1-19.Disponible en: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3969803/

  15. Hu ZY, Xiao L, Bode AM, Dong Z, Cao Y. Glycolytic genes in cancer cells are more than glucose metabolic regulators. J Mol Med . 2014 [citado 2 jun 2014]; 92(8):837-845. Disponible en: http://link.springer.com/article/10.1007/s00109-014-1174-x

  16. Matoba S, Kang JG, Patino WD, Wragg A, Boehm M, Gavrilova O, et al. p53 Regulates Mitochondrial Respiration. Science. 2006[citado 2 jun 2014]; 312(5780):1650-1653.Disponible en: http://www.ncbi.nlm.nih.gov/pubmed/16728594

  17. Denko NC. Hypoxia, HIF1 and glucose metabolism in the solid tumor. Nat Rev Cancer. 2008 [citado 2 jun 2014]; 8(9):705-713.Disponible en: http://www.nature.com/nrc/journal/v8/n9/full/nrc2468.html

  18. Gaglio D, Metallo CM, Gameiro PA, Hiller K, Danna LS, Balestrieri C, et al. Oncogenic K-Ras decouples glucose and glutamine metabolism to support cancer cell growth. Mol Syst Biol. 2011 [citado 2 jun 2014]; 7(1):1-15.Disponible en: http://onlinelibrary.wiley.com/doi/10.1038/msb.2011.56/full

  19. Chin L, Tam A, Pomerantz J, Wong M, Holash J, Bardeesy N, et al. Essential role for oncogenic Ras in tumour maintenance. Nature. 1999[citado 2 jun 2014]; 400(6743):468–472.Disponible en: http://www.nature.com/nature/journal/v400/n6743/abs/400468a0.html

  20. Iqbal MA, Siddiqui FA, Chaman N, Gupta V, Kumar B, Gopinath P, et al. Missense mutations in pyruvate kinase M2 promote cancer metabolism, oxidative endurance, anchorage independence, and tumor growth in a dominant negative manner. J Biol Chem.2014 [citado 2 jun 2014]; 289(12):8098-8105.Disponible en: http://www.jbc.org/content/289/12/8098.full.pdf

  21. Kroemer G, Pouyssegur J. Tumor Cell Metabolism: Cancer's Achilles ‘ heel. Cancer Cell. 2008[citado 1 feb 2016]; 13(16):472-482. Disponible en: http://www.sciencedirect.com/science/article/pii/S1535610808001608

  22. Mathupala SP, Ko YH, Pedersen PL. Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitocondria. Oncogene. 2006 [citado 2 jun 2014]; 25(34):4777–4786.Diponible en: http://www.nature.com/onc/journal/v25/n34/full/1209603a.html

  23. Swinnen JV, Roskams T, Joniau S, Van Poppel H, Oyen R, Baert L, et al. Overexpression of fatty acid synthase is an early and common event in the development of prostate cancer. Int J Cancer.2002 [citado 2 jun 2014]; 98(1):19-22.Disponible en: http://onlinelibrary.wiley.com/doi/10.1002/ijc.10127/full

  24. Vander Heiden MG, Lunt SY, Dayton TL, Fiske BP, Israelsen WJ, Mattaini KR, et al. Metabolic Pathway Alterations that Support Cell Proliferation. Cold Spring Harb Symp Quant Biol. 2011 [citado 2 jun 2014]; 76:325-334.Disponible en: http://symposium.cshlp.org/content/76/325.full

  25. Kato Kaneko M, Liu X, Oki H, Ogasawara S, Nakamura T, Saidoh N, et al. Isocitrate dehydrogenase mutation is frequently observed in giant cell tumor of bone. 2014. Cancer Sci.2014 [citado 2 jun 2014]; 105(6):744-748.Disponible en: http://onlinelibrary.wiley.com/doi/10.1111/cas.12413/abstract

  26. Grassian AR, Parker SJ, Davidson SM, Divakaruni AS, Green CR, Zhang X, et al. IDH1 Mutations Alter Citric Acid Cycle Metabolism and Increase Dependence on Oxidative Mitochondrial Metabolism. Cancer Res.2014 [citado 2 jun 2014]; 74(12):3317-3331. Disponible en: http://cancerres.aacrjournals.org/content/74/12/3317.abstract

  27. Fathi AT, Sadrzadeh H, Comander AH, Higgins MJ, Bardia A, Perry A, et al. Isocitrate Dehydrogenase 1 (IDH1) Mutation in Breast Adenocarcinoma Is Associated With Elevated Levels of Serum and Urine 2-Hydroxyglutarate.Oncologist.2014[citado 2 jun 2014];19(6):602-607. Disponible en: http://theoncologist.alphamedpress.org/content/19/6/602.full.pdf+html

  28. Wang JH, Chen WL, Chen SJ. Prognostic significance of 2-hydroxyglutarate levels in acute myeloid leukemia in China.Proc Natl Acad Sci USA. 2013 [citado 2 jun 2014]; 110(42):17017-17022.Disponible en: http://www.pnas.org/content/110/42/17017.short

  29. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase–AKT pathway in human cáncer. Nat. Rev. Cancer. 2002 [citado 2 jun 2014]; 2(7):489-501.Disponible en: http://www.nature.com/nrc/journal/v2/n7/abs/nrc839.html

  30. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The Biology of Cancer: Metabolic Reprogramming Fuels Cell Growth and Proliferation. Cell Metabolism. 2008 [citado 2 jun 2014]; 7(1):11-20.Disponible en: http://www.sciencedirect.com/science/article/pii/S1550413107002951

  31. Elstrom RL, Bauer DE, Buzzai M , Karnauskas R, Harris MH , Plas DR, et al . Akt stimulates aerobic glycolysis in cancer cells. Cancer Res.2004 [citado 2 jun 2014]; 64(11):3892-3899.Disponible en: http://cancerres.aacrjournals.org/content/64/11/3892.short

  32. Plas DR, Thompson CB. Akt-dependent transformation: there is more to growth than just surviving. Oncogene. 2005 [citado 2 jun 2014]; 24(50):7435–7442.Disponible en: http://www.nature.com/onc/journal/v24/n50/full/1209097a.html

  33. Wakil SJ. Fatty acid synthase, a proficient multifunctional enzyme. Biochemistry.1989 [citado 2 jun 2014]; 28(11):4523–4530.Disponible en: http://pubs.acs.org/doi/abs/10.1021/bi00437a001

  34. Hatzivassiliou G, Zhao F, Bauer DE, Andreadis C, Shaw AN, Dhanak D, et al. ATP citrate lyase inhibition can suppress tumor cell growth. Cencer Cell .2005 [citado 2 jun 2014]; 8(4):311-321.Disponible en: http://www.sciencedirect.com/science/article/pii/S1535610805003016

  35. Yang C, Sudderth J, Dang T, Bachoo R, McDonald JG, DeBerardinis RJ. Glioblastoma Cells Require Glutamate Dehydrogenase to Survive Impairments of Glucose Metabolism or Akt Signaling. Cancer Res. 2009 [citado 2 jun 2014]; 69(20):7986–7993.Disponible en: http://cancerres.aacrjournals.org/content/69/20/7986.short

  36. Gabay M, Li Y, Felsher DW. MYC Activation Is a Hallmark of Cancer Initiation and Maintenance. Cold Spring Harb Perspect Med. 2014[citado 2 jun 2014]; 4(6).Disponible en: http://perspectivesinmedicine.cshlp.org/content/4/6/a014241.short

  37. Dang CV, Le A, Gao P. MYC-Induced Cancer Cell Energy Metabolism and Therapeutic Opportunities. Clin Cancer Res.2009 [citado 2 jun 2014]; 15(21):6479-6483.Disponible en: https://clincancerres.aacrjournals.org/content/15/21/6479.full




2020     |     www.medigraphic.com